Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Recombinant Human Coagulation Factor Ⅷ-Fc Fusion Protein (FRSW117) for Injection in Patients With Severe Hemophilia A (Adults and Adolescents)

NCT06142552 is registered in ClinicalTrials.gov with Hangzhou Gensciences Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06142552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06142552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Recombinant Human Coagulation Factor Ⅷ-Fc Fusion Protein (FRSW117) for Injection in Patients With Severe Hemophilia A (Adults and Adolescents)
Lead sponsor
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 27, 2023
Completion date
October 19, 2025
Enrollment
124 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia a